Oxford Biomedica PLC

Director's Dealing • Jan 2, 2026

National Storage Mechanism | Additional information

RNS Number : 2000N

Oxford Biomedica PLC

02 January 2026

Name of applicant:		OXFORD BIOMEDICA PLC
Name of scheme:		2015 Employee Share Option Scheme
Period of return:	From:	1 July 2025	To:	31 December 2025
Balance of unallotted securities under scheme(s) from previous return:		280,836
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		13,800
Equals:  Balance under scheme(s) not yet issued/allotted at end of period:		267,036
Name of applicant:		OXFORD BIOMEDICA PLC
Name of scheme:		2015 and 2024 Long Term Incentive Plan
Period of return:	From:	1 July 2025	To:	31 December 2025
Balance of unallotted securities under scheme(s) from previous return:		990,229
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		362,154
Equals:  Balance under scheme(s) not yet issued/allotted at end of period:		628,075
Name of applicant:		OXFORD BIOMEDICA PLC
Name of scheme:		2015 and 2024 Deferred Bonus Plan
Period of return:	From:	1 July 2025	To:	31 December 2025
Balance of unallotted securities under scheme(s) from previous return:		522,449
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		128,536
Equals:  Balance under scheme(s) not yet issued/allotted at end of period:		393,913
Name of applicant:		OXFORD BIOMEDICA PLC
Name of scheme:		Sharesave Scheme
Period of return:	From:	1 July 2025	To:	31 December 2025
Balance of unallotted securities under scheme(s) from previous return:		339,040
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		190,364
Equals:  Balance under scheme(s) not yet issued/allotted at end of period:		148,676
48

Name of contact:	Natalie Walter, Chief Legal Officer and Group Company Secretary
Telephone number of contact:	01865 783000

-Ends-

Enquiries:       

OXB:

Natalie Walter, Chief Legal Officer and Group Company Secretary - T: +44 (0) 1865 783 000 / E: [email protected]

About OXB

OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB's world-class capabilities range from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

OXB offers a vast number of technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.

OXB, a FTSE250 and FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, Bedford MA, and Durham NC, US. Learn more at www.oxb.com and follow us on LinkedIn and YouTube.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BLRTMBRTMTJJBFA